Informations générales (source: ClinicalTrials.gov)
Evaluation of the Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical Cancer at an Advanced Stage. Multicenter Prospective Observational Study (COLTEP)
Observational
University Hospital, Brest (Voir sur ClinicalTrials)
janvier 2020
janvier 2026
29 juin 2024
A lot of studies have demonstrated the prognostic value of post therapy 18F-FDG PET/CT in
the management of uterine cervical cancer. Post therapy 18F-FDG PET/CT is usually
requested by a lot of clinicians.
Whereas 18F-FDG PET/CT is useful for prognosis in the follow-up, data are yet
insufficient to clearly establish a formal recommendation.
This prospective multicenter observational study will evaluate the interest of post
therapy 18F-FDG PET/CT in clinical management (within 2 months of treatment) in patients
with cervical cancer at an advanced stage.
Main outcome :
The therapeutic impact of post therapy 18F-FDG PET/CT (within 2 months after the end of
therapy) will be evaluated on the complete results included MRI.
Investigators will compare :
- decision of clinicians without 18F-FDG PET/CT results
- and decision of clinicians knowing entire results included results of 18F-FDG
PET/CT.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Henri Becquerel - 76038 - Rouen - France | Agathe EDET-SANSON | Contact (sur clinicalTrials) | |||
| CHRU de Brest (Hôpital Morvan) - 29200 - Brest - France | Alexandra LE DUC-PENNEC | Contact (sur clinicalTrials) | |||
Critères
Femme
Inclusion Criteria:
- Patient old ≥ 18 years
- Uterine cervical cancer with locally-advanced (FIGO 2019 IB3 to IVA)
- Histology: squamous cell carcinoma and adenocarcinoma
- Feasibility of a curative treatment
- Having formulated a non-opposition
- Patient old ≥ 18 years
- Uterine cervical cancer with locally-advanced (FIGO 2019 IB3 to IVA)
- Histology: squamous cell carcinoma and adenocarcinoma
- Feasibility of a curative treatment
- Having formulated a non-opposition
- Minor patient < 18 years
- Pregnancy or breastfeeding
- Other type of tumor than squamous cell carcinoma and adenocarcinoma
- FIGO 2019 < IB3 or > IVA
- Non-eligibility for the examination
- Contraindication to MRI and PET/CT
- Previous history of cancer
- Refusal of participation